Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations-Reference-Cited by-同舟云学术

Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations

Published:2022-04 Issue:2 Volume:413 Page:113078
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Yamaguchi Miki,Hirai Sachie^ORCID,Idogawa Masashi^ORCID,Uchida Hiroaki,Sakuma Yuji^ORCID

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cell Biology

Reference19 articles.

1. MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations;Socinski;JCO Precis Oncol,2021

2. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations;Santarpia;Transl. Lung Cancer Res.,2021

3. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies;Wu;Cancer Treat Rev.,2021

4. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations;Paik;N. Engl. J. Med.,2020

5. GEOMETRY mono-1 investigators. Capmatinib in MET exon 14-mutated or MET -amplified non-small-cell lung cancer;Wolf;N. Engl. J. Med.,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Newly Developed Anti-L1CAM Monoclonal Antibody Targets Small Cell Lung Carcinoma Cells;International Journal of Molecular Sciences;2024-08-11

2. Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma;Experimental Cell Research;2023-05

3. Metabolic regulation and antihyperglycemic properties of diet-derived PGG through transcriptomic and metabolomic profiling;Food & Function;2023

4. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells;Biochemical and Biophysical Research Communications;2022-11